Researchers studied data from 10,204 young women in Alberta, Canada, an area that has implemented a school-based HPV vaccination program. About 56 percent of the women in the study were unvaccinated, with the remainder receiving at least one HPV vaccine before having a cervical cancer screening, according to a Reuters report.
Here are six things to know about the study’s findings:
- About 14.5 percent of women had abnormal Pap tests and 85.5 percent had normal results.
- Nearly 94 percent of the abnormal tests were low-grade abnormalities, with the other 6 percent being more serious abnormalities that could lead to cervical cancer.
- Less than 12 percent of women who received three doses of the vaccine had abnormal Pap results. About 16 percent of unvaccinated women had abnormal tests.
- This data translates into a 28 percent risk reduction with a full HPV vaccination.
- When only high-grade abnormalities were included, there was a 50 percent reduction in risk.
- Incomplete HPV vaccination — receiving less than the recommended three doses — did not lower the risk of having an abnormal Pap test. Women who had two doses of the vaccine had similar odds of having an abnormal test as women who received zero doses.
More articles on infection control & clinical quality:
Red Cross launches emergency appeal for funds to combat yellow fever
After measles outbreak, Arizona health officials urge detention facility workers to get vaccinated Initiatives aimed at lowering hospital admissions also lower readmissions, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.